Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sangeeta Krishnan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Patient Preference and Adherence|December 10, 2015
Patient and parent preferences for characteristics of prophylactic treatment in hemophiliaRoberto Furlan, Sangeeta Krishnan, Jeffrey Vietri
Seminars in Cardiothoracic and Vascular Anesthesia|December 3, 2009
Choice of hemostatic agent and hospital length of stay in cardiovascular surgerySangeeta Krishnan, Therese M Conner, Ryan Leslie, et al.
Journal of Medical Economics|August 12, 2014
Costs and utilization of hemophilia A and B patients with and without inhibitorsEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Hematology (Amsterdam, Netherlands)|July 9, 2014
Adherence to clotting factors among persons with hemophilia A or BEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Seminars in Cardiothoracic and Vascular Anesthesia|December 1, 2009
Current concepts in reoperative cardiac surgeryJoanna Chilwe, Sangeeta Krishnan, Therese M Conner, et al.
Journal of Medical Economics|November 26, 2016
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumptionAlfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, et al.
Orthopedics|June 14, 2012
Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKAJames L Comadoll, Shea Comadoll, Audrey Hutchcraft, et al.
Advances in Therapy|March 22, 2022
Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal HemoglobinuriaSangeeta Krishnan, Sujata Sarda, Colin Kunzweiler, et al.
Annals of Hematology|January 1, 2022
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient surveyDavid Dingli, Joana E Matos, Kerri Lehrhaupt, et al.
Advances in Therapy|July 18, 2021
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US PopulationWendy Y Cheng, Sujata P Sarda, Nikita Mody-Patel, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Patient Preference and Adherence|December 10, 2015
Patient and parent preferences for characteristics of prophylactic treatment in hemophiliaRoberto Furlan, Sangeeta Krishnan, Jeffrey Vietri
Seminars in Cardiothoracic and Vascular Anesthesia|December 3, 2009
Choice of hemostatic agent and hospital length of stay in cardiovascular surgerySangeeta Krishnan, Therese M Conner, Ryan Leslie, et al.
Journal of Medical Economics|August 12, 2014
Costs and utilization of hemophilia A and B patients with and without inhibitorsEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Hematology (Amsterdam, Netherlands)|July 9, 2014
Adherence to clotting factors among persons with hemophilia A or BEdward P Armstrong, Daniel C Malone, Sangeeta Krishnan, et al.
Seminars in Cardiothoracic and Vascular Anesthesia|December 1, 2009
Current concepts in reoperative cardiac surgeryJoanna Chilwe, Sangeeta Krishnan, Therese M Conner, et al.
Journal of Medical Economics|November 26, 2016
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumptionAlfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, et al.
Orthopedics|June 14, 2012
Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKAJames L Comadoll, Shea Comadoll, Audrey Hutchcraft, et al.
Advances in Therapy|March 22, 2022
Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal HemoglobinuriaSangeeta Krishnan, Sujata Sarda, Colin Kunzweiler, et al.
Annals of Hematology|January 1, 2022
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient surveyDavid Dingli, Joana E Matos, Kerri Lehrhaupt, et al.
Advances in Therapy|July 18, 2021
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US PopulationWendy Y Cheng, Sujata P Sarda, Nikita Mody-Patel, et al.
Pageof 2